BioSpace News Archive

OcuTerra Therapeutics, Inc. today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place on January 8-11, 2024 in San Francisco.

Apertura Gene Therapy today unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1).

Moonwalk Biosciences, a genomic medicine company pioneering precision epigenetic medicines, today announced the completion of $57 million in seed and Series A financing from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures.

MMI (Medical Microinstruments, Inc.) today announced the company has been invited to participate in the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco.

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today that Chief Executive Officer Dr. Usman “Oz” Azam, M.D., will participate in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 8:30am PT / 11:30am ET.

Ashvattha Therapeutics announced the appointment of Mehdi Paborji, Ph.D., as Senior Vice President of Technical Operations.

GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental health care, announces the official launch of Prism for PTSD in the United States.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes.

RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”) is pleased to announce the publication of a case report in Heliyon, Cell Press’s peer-reviewed journal (available at https://www.cell.com/heliyon/pdf/S2405-8440(23)10960-1.pdf) involving a 19-year old patient with pharmaco-resistant epilepsy.

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 5:15 p.m. ET.